Savolitinib

Research use only, not for human use.

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50s of 5 nM and 3 nM for c-Met and p-Met.

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity.

——

Animal Model:U87MG xenograft model in athymic nude mice Dosage:1 mg/kg, 2.5 mg/kg and 10.0 mg/kg Administration:Oral administration; daily; for 21 days Result:Demonstrated dose-dependent tumor growth inhibition in a U87MG subcutaneous xenograft model.

——

Angiogenesis

c-Met/HGFR

——

——

——

1313725-88-0

345.36

C??H??N?

>98% (HPLC)

DMSO : 25 mg/mL (72.39 mM; Need ultrasonic);H2O : < 0.1 mg/mL (insoluble)

CN1N=CC(C2=CN=C3C(N([C@H](C4=CN5C(C=C4)=NC=C5)C)N=N3)=N2)=C1

——

(-20℃)

With Ice Pack

≥ 2 years